LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

28.18 -1.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.44

Max

28.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+126.46% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	32M 1.5B
Ankstesnė atidarymo kaina	29.58
Ankstesnė uždarymo kaina	28.18

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-05 19:20; UTC

Pagrindinės rinkos jėgos

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026-06-05 21:27; UTC

Uždarbis

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026-06-05 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026-06-05 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026-06-05 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Hog Futures Tumble to Close Week -- Market Talk

2026-06-05 19:10; UTC

Rinkos pokalbiai

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026-06-05 19:03; UTC

Rinkos pokalbiai

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026-06-05 18:59; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026-06-05 18:47; UTC

Rinkos pokalbiai

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026-06-05 18:34; UTC

Rinkos pokalbiai

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026-06-05 18:33; UTC

Įsigijimai, susijungimai, perėmimai

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026-06-05 17:50; UTC

Uždarbis

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026-06-05 17:27; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026-06-05 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 15:26; UTC

Rinkos pokalbiai

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026-06-05 15:25; UTC

Uždarbis

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026-06-05 15:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 15:16; UTC

Rinkos pokalbiai

Zcash Tumbles After Exploit Found -- Market Talk

2026-06-05 15:09; UTC

Rinkos pokalbiai

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

2026-06-05 15:07; UTC

Rinkos pokalbiai

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

2026-06-05 15:05; UTC

Rinkos pokalbiai

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

126.46% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 126.46%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.